Two Connecticut Complete Care Centers Earn National Quality Award
Recognition signifies a formal commitment to continuous improvement in quality care EAST HARTFORD, CT / ACCESS Newswire / June 14,...
Day: June 14, 2026
Three Mid-Atlantic Complete Care Centers Earn National Quality Award
Recognition signifies a formal commitment to continuous improvement in quality care BALTIMORE, MD / ACCESS Newswire / June 14, 2026...
Complete Care at Southpointe Earns National Quality Award for Commitment to Quality Care
Recognition signifies a formal commitment to continuous improvement in quality care GREENFIELD, WI / ACCESS Newswire / June 14, 2026...
Eight New Jersey Complete Care Centers Earn National Quality Award for Commitment to Quality Care
Recognition signifies a formal commitment to continuous improvement and excellence in resident care TOMS RIVER, NJ / ACCESS Newswire /...
Canadian Health IT Buyers Bring a Connected-Care Growth Agenda to e-Health26: Interoperability, Trusted Data and Measurable ROI
Black Book's 2026 Canada Digital Health Market Outlook finds a decisive shift from digitization to proof-driven procurement, with Canadian vendors...
HorseWood & HorseBoost [Exclusive Report 2026] The Horse Gelatin Trick Male Enhancement Or Why Talking About Natural Vitality Supplement Horse Boost?
Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what...
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction...
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I...
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL...
KFSH Highlights Human-Centered AI as a Path to Better Care at HLTH Europe 2026
RIYADH, Saudi Arabia, June 14, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe 2026 in Amsterdam, taking place from June 15...
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% of...
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Media ReleaseCOPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early...
HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained
Sublingual Compounded Vardenafil, Sildenafil, Tadalafil, and Apomorphine for Prescription ED Treatment: 10-Minute Onset and 36-Hour Active Window ResearchedKennewick, WA, June...
KFSH Showcases Trusted AI as the Foundation for Scalable Healthcare Transformation at HLTH Europe 2026
RIYADH, Saudi Arabia, June 13, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) will use its...